Lung Cancer Updates—2017 Oncology Annual Meeting
prIME Downloadable Slides
prIME Downloadable Slides

Lung Cancer Updates—2017 Oncology Annual Meeting

Not a member of My prIME? Join now for instant access.

prIME Downloadable Slides in Lung Cancer From the 2017 Oncology Annual Meeting in Chicago

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit™

Release Date

Release Date

Jun 15, 2017

Expiration Date

Jun 15, 2018

Featured Expert

  • Jamie E. Chaft, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Abstract #8508: Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers

Featured Expert

  • Julie Brahmer, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States

Featured Topic

Abstract #9000: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024

Featured Expert

  • Fernando Costa Santini, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Abstract #9012: Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy

Featured Expert

  • Ahmad Tarhini, MD , University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Featured Topic

Abstract #9014: Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care

This educational activity is supported by a grant from Merck and Co., Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Lung Cancer Updates—2017 Oncology Annual Meeting - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 100%.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Dr Brahmer has disclosed that she has received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene, Lilly, and Merck. She has performed contracted research for Bristol-Myers Squibb, MedImmune/Astrazeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Chaft has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Santini has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tarhini has disclosed that he has performed contracted research for Incyte and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Elizabeth Cameron, PhD (clinical content planner/reviewer) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.